Scientific summarizing of the results of expert evaluation of anticancer drugs for the treatment of gastric and colorectal cancer
DOI:
https://doi.org/10.14739/2310-1210.2013.5.19028Keywords:
anticancer drugs, stomach cancer, rectum cancer, expert evaluation, formularAbstract
Introduction. Every year in Ukraine more than 160,000 new cases of cancer are registered, the number of deaths from the disease each year is more than 87,000. Over the last decade in Ukraine gastric cancer have took third place in the structure of cancer incidence among men and fourth in women. At the same time, since 2009, the main cause of adult deaths from malignant tumors in Ukraine is colorectal cancer. According to the forecasts of the Ministry of Health under the conditions, the situation in the Ukraine will be continued to 2020. So important is the issue of improving the existing pharmaceutical care for this group of patients.
Thus, the aim of the work was a comprehensive expertise of anticancer drugs for the treatment of cancer patients with abdominal profile.
As a method of research the method of expert evaluation was used (oncologists-chemotherapeutist). The authors had developed an algorithm for expert evaluation of anticancer drugs used in pathogenetic therapy of stomach cancer and colorectal (rectal) cancer.
Questionnaire for oncologists was designed by researchers of Organization and economy of pharmacy department led by professor Nemchenko A.S. and successfully used in conducting of fundamental researches from 1998; questionnaire proposed to assess 48 anticancer drugs.
The study was carried out in eight basic regions in which structure of morbidity corresponds to the general structure in the country. Previously the coefficient of competence of each expert have been calculated. For further research authors used questionnaires of the experts with very high, high and sufficient competence, accounting for nearly 65% of the questionnaires.
Tothe high-level group of drugs experts allocated 24 anticancer medicines, corresponding to 8 INN, in group of middle- experts identified 16 anticancer medicines or 9 INN. Thus, 80% of the researched medicines were recommended by experts or inclused in the formulary lists for treatment stomach and rectal cancer.
In conclusion, it should be noted that, in general, the recommended list of the drugs mainly corresponded to the current state protocols of treatment of patients with stomach and rectal cancer.
References
Воробьев П.А. Клинико-экономический анализ в медицинской организации. Практическое руководство для лиц, принимающих решения / Воробьев П.А. // Рациональная фармакотерапия. – 2008. – №1 (10). – С. 5 14.
Немченко А.С. Клініко-економічний аналіз фармацевтичного забезпечення хворих на рак молочної залози / А.С. Немченко, М.В. Подгайна // Вісник фармації. – 2009. – №1 (59). – С. 50–53.
Немченко А.С. Наукове узагальнення результатів моніторингу цін та доступності протипухлинних препаратів для лікування раку шлунка та раку прямої кишки / А.С. Немченко, С.О. Жаркова, М.В. Подгайна // Управління, економіка та забезпечення якості в фармації. – Харків, МНМТ. – №4 (24). – 2012. – С. 60–64.
Немченко А.С. Результати клініко-економічного аналізу фармакотерапії хворим на рак шлунка та рак прямої кишки в Україні / А.С. Немченко, С.О. Жаркова, М.В. Подгайна // Мат. міжнародної науково-практичної конференції «Оцінка медичних технологій та можливі механізми її впровадження в Україні», 16 жовтня 2012. – К., 2012. – С. 14.
Немченко А.С. Експертна оцінка лікарських препаратів, які застосовуються у лікуванні хворих на наркозалежність / А. С. Немченко, О. С. Яковлева // Управління, економіка та забезпечення якості в фармації. – Харків, МНМТ. – №1 (21). – 2012. – С. 68–72.
Панфілова Г.Л. Розробка організаційно-економічних заходів щодо включення статинів у формулярні переліки / Г.Л. Панфілова, Ю.В. Корж // Управління, економіка та забезпечення якості в фармації. – 2008. – Т. 1, №2. – С. 48 53.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
